De Sarro G, De Sarro A, Di Paola E D, Bertorelli R
Department of Experimental and Clinical Medicine, School of Medicine, University of Catanzaro, Italy.
Eur J Pharmacol. 1999 Apr 29;371(2-3):137-45. doi: 10.1016/s0014-2999(99)00132-6.
We have studied the effects of selective and non-selective adenosine receptor agonists and antagonists in audiogenic-seizure-sensitive DBA/2 mice, an animal model of generalized reflex epilepsy. With the exception of the adenosine A3 receptor agonist, N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (IB-MECA), all the agonists studied prevented the development of audiogenic seizures in a dose-dependent manner. The ED50 values against the clonic phase of the audiogenic seizures were low, that is: 0.06 mg/kg, i.p., for the adenosine A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), 0.02 and 0.03 mg/kg, i.p., for the adenosine A2A receptor agonists, 2-(4-(2-carboxyethyl)-phenylamino)-5'-N-ethylcarboxamidoadenosine (CGS 21680) and 2-hexynyl-5'-N-ethyl-carboxamidoadenosine (2-HE-NECA), and 0.7 mg/kg, i.p., for the adenosine A1/A3 receptor agonist, N6-2-(4-aminophenyl)ethyladenosine (APNEA). Conversely, the non-selective agonist, N-ethyl-carboxamidoadenosine (NECA), was highly potent, the ED50 being 0.0005 mg/kg, i.p. In the absence of auditory stimulation, the adenosine receptor antagonists increased the incidence of both clonic and tonic seizures in DBA/2 mice. The ED50 values were: for caffeine, 207.5 mg/kg, i.p., for the adenosine A1 receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 327.8 mg/kg i.p., for the adenosine A2A receptor antagonists, 3,7-dimethyl-1-propylxanthine (DPMX), 86.7 mg/kg i.p., for the (E,18%-Z,82%)7-methyl-8-(3,4-dimethoxystyryl)-1,3-dipropylxanthine (KF 17837), 69.1 mg/kg i.p., and 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-(4,3-c)1,2,4-triazolo(1,5 -c)-pyrimidine (SCH 58261), 321.8 mg/kg i.p. The rank order of convulsant potency in our epileptic model, following intracerebroventricular administration, was DPCPX > DMPX > 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (CSC) > KF 17837 > Caffeine > SCH 58261 > 5-amino-9-chloro-2-(2-furyl)-1,2,4-triazolo(1,5-c)quinazoline (CGS 15943). Following a subconvulsant audiogenic stimulus of 83 dB, all adenosine receptor antagonists induced both tonic and clonic seizures. The ED50 values for such proconvulsant effects were: for caffeine 0.04 mg/kg, i.p., for the adenosine A receptor antagonist, DPCPX, 5.84 mg/kg, i.p., for the adenosine A2A receptor antagonists, DMPX, 0.02 mg/kg, i.p., CGS 15943, 0.29 mg/kg i.p., KF 17837, 0.57 mg/kg, i.p., CSC 0.12 mg/kg, i.p. and SCH 58261 0.07 mg/kg, i.p., respectively. These data suggest that stimulation of adenosine A1 and A2A receptors is involved in the suppression of seizures.
我们研究了选择性和非选择性腺苷受体激动剂及拮抗剂对听源性癫痫敏感的DBA/2小鼠(一种全身性反射性癫痫动物模型)的影响。除腺苷A3受体激动剂N6-(3-碘苄基)-5'-N-甲基羧酰胺腺苷(IB-MECA)外,所有研究的激动剂均以剂量依赖方式预防听源性癫痫的发作。针对听源性癫痫阵挛期的半数有效剂量(ED50)值较低,即:腺苷A1受体激动剂2-氯-N6-环戊基腺苷(CCPA)腹腔注射的ED50为0.06 mg/kg;腺苷A2A受体激动剂2-(4-(2-羧乙基)-苯氨基)-5'-N-乙基羧酰胺腺苷(CGS 21680)和2-己炔基-5'-N-乙基羧酰胺腺苷(2-HE-NECA)腹腔注射的ED50分别为0.02和0.03 mg/kg;腺苷A1/A3受体激动剂N6-2-(4-氨基苯基)乙基腺苷(APNEA)腹腔注射的ED50为0.7 mg/kg。相反,非选择性激动剂N-乙基羧酰胺腺苷(NECA)效力很强,腹腔注射的ED50为0.0005 mg/kg。在无听觉刺激的情况下,腺苷受体拮抗剂增加了DBA/2小鼠阵挛性和强直性癫痫的发生率。ED50值分别为:咖啡因腹腔注射为207.5 mg/kg;腺苷A1受体拮抗剂8-环戊基-1,3-二丙基黄嘌呤(DPCPX)腹腔注射为327.8 mg/kg;腺苷A2A受体拮抗剂3,7-二甲基-1-丙基黄嘌呤(DPMX)腹腔注射为86.7 mg/kg;(E,18%-Z,82%)7-甲基-8-(3,4-二甲氧基苯乙烯基)-1,3-二丙基黄嘌呤(KF 17837)腹腔注射为69.1 mg/kg;5-氨基-7-(2-苯乙基)-2-(2-呋喃基)-吡唑并-(4,3-c)1,2,4-三唑并(1,5 -c)-嘧啶(SCH 58261)腹腔注射为321.8 mg/kg。在我们的癫痫模型中,脑室内给药后惊厥效力的排序为:DPCPX > DMPX > 1,3,7-三甲基-8-(3-氯苯乙烯基)黄嘌呤(CSC)> KF 17837 > 咖啡因 > SCH 58261 > 5-氨基-9-氯-2-(2-呋喃基)-1,2,4-三唑并(1,5-c)喹唑啉(CGS 15943)。在83 dB的亚惊厥性听源性刺激后,所有腺苷受体拮抗剂均诱发了强直性和阵挛性癫痫。这种促惊厥作用的ED50值分别为:咖啡因腹腔注射0.04 mg/kg;腺苷A受体拮抗剂DPCPX腹腔注射5.84 mg/kg;腺苷A2A受体拮抗剂DMPX腹腔注射0.02 mg/kg、CGS 15943腹腔注射0.29 mg/kg、KF 17837腹腔注射0.57 mg/kg、CSC腹腔注射0.12 mg/kg以及SCH 58261腹腔注射0.07 mg/kg。这些数据表明,腺苷A1和A2A受体的刺激参与了癫痫发作的抑制。